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Abstract  
Huntington Disease (HD) is a hereditary brain disease. Although the causative gene 
has been found, the exact mechanisms of the pathogenesis are still unknown. Recent 
investigations point to a metabolic and energetic dysfunction in HD neurons. 
In this study, proton nuclear magnetic resonance spectroscopy (1H NMR) was used to 
analyse serum and cerebrospinal fluid (CSF) taken from presymptomatic HD 
transgenic rats and their wild-type littermates. Both univariate and multivariate 
analyses were used to compare these metabolic profiles. N-acetylaspartate (NAA), an 
indicator of neuronal function, was found to be significantly decreased in the serum of 
HD rats compared to wild-type littermates. In addition, levels of glucose, lactate, 
glutamine and succinic acid are significantly increased in the serum of HD rats. 
Moreover, the increased concentration of glucose and lactate can also be found in the 
CSF of transgenic rats. There is a 1:1 stoichiometry coupling glucose utilization and 
glutamate cycling. The observed increase in the glutamine concentration, which 
indicates a shutdown in the neuronal-glial glutamate-glutamine cycling, results 
therefore also in an increased glucose concentration. The elevated succinic acid 
concentration might be due to an inhibition of succinate dehydrogenase, an enzyme 
linked to the mitochondrial respiratory chain and TCA cycle. Moreover, reduced 
levels of NAA may reflect an impairment of mitochondrial energy production. In 
addition, the observed difference in lactate supports a deficiency of oxidative energy 
metabolism in rats transgenic for HD as well. 
The observed metabolic alterations seem to be more profound in serum in comparison 
to CSF in presymptomatic rats. All findings suggest that even in presymptomatic rats, 
a defect in the energy metabolism is already apparent. Moreover, these results support 
the hypothesis of a mitochondrial energy dysfunction in HD. 
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1. Introduction 
Huntington Disease (HD) is an autosomal dominant neurodegenerative disorder, 
characterized by progressive motor, cognitive and psychiatric dysfunctions. Although 
the disease can occur at any age, the median age of onset is 40 years. Most patients 
die one to two decades after disease onset. 
HD is caused by a mutation in the gene coding for the protein Huntingtin. The exact 
function of this protein is still unknown. Normal individuals have a CAG-
trinucleotide repeat length of less than 37 [1]. People whose CAG repeat length 
exceeds this number will develop HD. The length of the CAG expansion is 
proportional to the severity of the disease and inversely proportional to the age of 
onset [2]. At present, the exact mechanism of the HD pathology is still unknown. 
However, recent evidence points to metabolic and energetic dysfunction in HD 
neurons [2-4]. Better knowledge about this mechanism is expected to lead to more 
appropriate analyses, which in turn should result in a better understanding of the 
disease. Moreover, this will help to direct the quest for improved treatments in the 
proper direction. 
According to Nicholson et al [5], metabolomics is defined as ‘the quantitative 
measurement of the dynamic multiparametric metabolic response of living systems to 
pathophysiological stimuli or genetic modifications’. Since 1999, applications of this 
technique have emerged in other fields (e.g. environmental sciences)[6]. Metabolites 
in biofluids are in dynamic equilibrium with those in cells and tissues. A healthy 
individual attempts to retain the concentration of metabolites in cells and tissues 
constant by homeostasis. Abnormal cellular processes due to sickness, toxins, etc. 
  
result in altered biofluid compositions. Various analytical techniques are available to 
detect low molecular weight metabolites. The ones most commonly applied in 
metabolomic studies are nuclear magnetic resonance spectroscopy (NMR) and mass 
spectrometry (MS). The latter is frequently used in combination with a 
chromatographic separation technique (liquid chromatography, gas chromatography, 
etc.) [7]. Although NMR is less sensitive than MS, this technique offers some 
important advantages. It is a high-throughput analysis that does not require any 
preceding chromatographic separation or purification procedure. Additionally, sample 
preparation is very straightforward. Furthermore, it is a non-destructive method 
capable of detecting all non-exchangeable protons, provided they are present above a 
certain threshold concentration (µM concentrations). Moreover, the measurements are 
very reproducible and inexpensive on a per sample basis [8-10]. All these advantages 
have contributed to the application of NMR spectroscopy in clinical diagnoses of 
diseases and in the follow-up of subjects participating in medical treatment studies 
[11].  
The NMR spectrum of a biofluid is generally extremely complex in nature, since each 
molecule present in the biofluid gives rise to one or several peaks in most cases. 
Moreover, many peaks show some fine structure and splittings which causes a 
prominent overlap of signals originating from different molecules [12]. Visual 
inspection of the spectra will therefore only reveal a small percentage of the available 
information [13].  
Spectral interpretation can be simplified by applying automatic data reduction 
methods. Subsequently, these reduced datasets can be analyzed with univariate [2,14-
22] or multivariate [13,23-27] statistical methods.  
  
In this study we applied 1H NMR spectroscopy in order to disentangle the metabolic 
profile of serum and cerebrospinal fluid (CSF) from a rat model for HD. Both 
univariate and multivariate statistical analyses were applied in a search for pathology 
specific differences. It is anticipated that these investigations lead to a gain in 
knowledge about the pathogenesis of HD and make it possible to identify some 
potential biomarkers. 
  
2. Materials and methods 
2.1 Animals 
Transgenic HD rats carrying a truncated huntingtin cDNA fragment with 51 CAG 
repeats under the control of the native rat huntingtin promoter, and their wild-type 
littermates were used [28]. The expressed gene product was 75 kDa, corresponding to 
22% of the full-length huntingtin (cDNA position 324-2321, amino acid position 1-
709/825, corresponding to exon 1-16), which are under the control of 886 bp of the rat 
huntingtin promoter (position 900 to 15). Genotyping was carried out as previously 
described [28]. The number of CAG-repeats was analyzed in a subset of transgenic 
rats using these primers: cggctgaggcagcagcggctgt (forward) and 
ccttcgagtccctcaagtccttc (reverse). The reverse primer is labelled at the 5’end with the 
fluorescent dye Cy5. The PCR amplicon length was then analyzed on the Beckman 
coulter sequencer (CEQ 8000 Cycle Sequencer, Krefeld, Germany). In more than 15 
generations only a small variation of ±1-2 CAGs were observed in transgenic rats of 
HD. Also for this study, in a subset of animals, the CAG-length was checked and it 
was found to be 51±2 CAGs. After genotyping, rats were housed in gender- and 
genotyped matched groups of two, according to FELASA recommendations. All rats 
were kept under a 12:12 hours light-dark cycle with lights on at 06.00 a.m. and food 
  
(Altromin lab chow pallets, Altromin standard diet: 1320; Lage, Germany) and tap 
water available ad libitum. All research and animal care procedures had been 
approved by the district government of Tuebingen, Germany, and followed principles 
described in the European Community’s Council Directive of 24th November, 1986 
(86/609/EEC). 
 For this study, we used serum and CSF from female, transgenic HD rats (n = 10 for 
serum and n = 8 for CSF) at an age of two months and compared these with age-
matched wild-type (WT) littermates (n = 12 for serum and respectively 9 for CSF). 
We are aware of the fact that the number of samples used in this study is rather small. 
However, this was determined by keeping in mind the well-being of animals and in 
order to reduce costs. Moreover, in the literature a lot of studies where even less 
samples per group are investigated, can be found [15,27,29-32]. 
2.2 Sample collection and preparation 
2.2.1 CSF samples 
Rats were sacrificed by CO2 inhalation and immediately exsanguinated. Subsequently, 
each animal was placed prone onto the stereotaxic instrument. A sagittal incision of 
the skin was made inferior to the occiput. The subcutaneous tissue and neck muscles 
through the midline were bluntly separated. Next, the rat was laid down in a way that 
the body made a 135° angle with the fixed head. In this angle, the dura mater of 
cisterna magna was exposed sufficiently. The dura was then penetrated with an insulin 
syringe and CSF was drawn. All samples were transferred into polypropylene tubes, 
immediately snap frozen in liquid nitrogen and stored at -80 °C until shipped for 
NMR analysis. Upon arrival, CSF samples were immediately stored at -80 °C until 
measurement. 
  
All CSF samples (40 µL) were simultaneously lyophilized. In cases where less then 
40 µL of CSF was available, the total available volume was lyophilized. The freeze-
dried samples were then stored at -20 °C in sealed vials until analysis. In order to keep 
the time spent at room temperature to a minimum, samples were randomly divided in 
five batches. Samples gathered in one batch were prepared together. Prior to NMR 
analysis, each sample was reconstituted in 8 µL sodium phosphate buffer (50 mM 
dissolved in D2O, pH = 7.05) containing 0.05 mM sodium azide in order to prevent 
bacterial contamination. Finally, this volume was transferred to a 1 mm NMR tube.  
2.2.2 Serum samples 
Samples were taken as done previously [33]. In short: rats were sacrificed with CO2 
and blood was drawn directly from the heart. All rats were tested for diabetics 
immediately after sample collection. The blood was incubated for one hour at 37 °C, 
followed by centrifugation for 30 minutes at 3000 x g.  The serum was collected and 
immediately stored at -80 °C until shipped for NMR analysis. Upon arrival, serum 
samples were immediately stored at -80 °C until measurement.  
In order to keep the time spent at room temperature to a minimum, samples were 
randomly divided in three groups. Samples assembled in one group were prepared 
together. Just before their acquisition, samples were thawed to room temperature. An 
aliquot of serum (250 µL) from each sample was mixed with 300 µL of an aqueous 
saline solution. In this way, each sample contains 0.1 M NaCl and 10 % D2O. The 
addition of an internal standard like DSS is prohibited by its interaction with proteins 
present in the sample. Subsequently, the total volume was transferred to a 5 mm NMR 
tube. 
  
2.3 1H NMR spectroscopy 
Prepared samples were analyzed on a Bruker Avance II-700 spectrometer, operating 
at a proton frequency of 700.13 MHz. The spectrometer is equipped with a BACS-60 
automatic sample changer and a 5 mm inverse TXI-Z probe when measuring serum 
samples. Since the brain volume of rats is rather small, the amount of CSF that can be 
collected at once from one animal is too small to perform a classical NMR analysis (> 
100 µL is necessary, prior to dilution to the final 550 µL measuring volume, in order 
to get a good S/N). Combining CSF taken from different animals within a population 
is not advisable, since this will remove the possibility to detect individual differences. 
Recently, Bach and co-workers [10,34] demonstrated that the use of a 1 mm probe 
setup provides an alternative to address the measurement of such volume restricted 
samples. Therefore, CSF samples were measured with a 1 mm inverse TXI-Z probe, 
requiring only 8 µL of sample volume. The samples were held at room temperature 
while on the sample changer and at 303 K during acquisition. Carr-Purcell-Meiboom-
Gill (CPMG) experiments were executed in order to get 1D 1H NMR spectra of the 
samples. The individual CMPG spin echo (in total 1 ms) was repeated 20 times, 
resulting in a total spin-spin relaxation delay of 20 ms. Suppression of the water signal 
was performed using 2.22 s presaturation during the relaxation delay. For each 
serum/CSF sample, 64 respectively 1024 scans, 32 K data points each, were 
accumulated. Each scan had an acquisition time of 0.78 s. To keep variation due to 
sample handling to a minimum, tuning and matching as well as shimming were 
performed automatically for each sample. Digital filtering was performed using the 
‘baseopt’ option available in Topspin 2.0 (Bruker Biospin Corporation) which results 
in flat baselines. Prior to Fourier transformation, the Free Induction Decays (FIDs) 
were zero-filled to 64 K and an exponential window function with a line broadening 
factor of 0.3 Hz was applied. The acquired NMR spectra were consecutively 
  
processed for phase and baseline correction. In the absence of an external reference 
(vide supra 2.2.2), all serum spectra were referenced to the methyl doublet of lactate 
at 1.33 ppm. After initial referencing of the CSF spectra using the anomeric glucose 
1H signal at 5.225 ppm, the spectra were still shifted one against the other. They were 
aligned using an in house developed spectral alignment algorithm (manuscript in 
preparation). 
2.4 Data reduction of the NMR spectra 
The 1H NMR spectra were automatically reduced into consecutive integrated spectral 
regions (buckets) of an equal width (0.05 ppm) applying R (version 2.7.2, 
http://www.r-project.org). In order to eliminate spectral variations due to different 
quality of water suppression from one spectrum to another, the region containing the 
water resonance (4.5-5.0 ppm) was not included in the analysis. In order to account 
for differences in concentration between samples, the subdivided spectra were scaled 
to their total intensity.  
2.4.1 Multivariate analysis 
Prior to multivariate analysis, the data were scaled to unit variance. Besides unit 
variance scaling, also pareto scaling and no scaling were tested on the dataset. 
However, these did not generate significant differences. Since all the variables possess 
an equal weight, irrespective of their absolute magnitude in the original data when 
unit variance scaling is applied, this method was preferred. 
Principal component analysis (PCA) is used to project the data in two or three 
dimension in order to be able to discern outliers. This method transforms the original 
variables in new, uncorrelated variables or principal components (PC) in such a way 
that the first PC represents most of the variation present in the original dataset. Higher 
PC will subsequently contain less amount of the variance [5,7,26].  
  
Partial least-squares discriminant analysis (PLS-DA) is a multivariate classification 
method based on PLS, a regression extension of PCA. This technique uses a priori 
knowledge about the data to maximize the separation between samples belonging to 
different classes [7,35]. Here, it concerns information about the pathological condition 
(healthy or HD) of each sample. The obtained scores plots are used to visualize the 
separation between the samples based on their class membership. The corresponding 
loadings plots contain information about the variables responsible for the observed 
separation. Both PCA and PLS calculations were performed with R (R version 2.7.2, 
http://www.r-project.org, packages FactoMineR version 1.14, caret version 4.76). A 
double cross-validation (2CV) strategy and permutation test [36] were applied to 
estimate the quality of the developed PLS-DA model. The data points were randomly 
divided into 5 fractions, of which one was used for testing, whereas the others were 
used for training and validation. Leave-one-out cross validation (LOOCV) [36] is 
used for validation in order to select the optimal model. LOOCV uses all but one data 
point as the training set. The left-out data point is used for validation. The data were 
randomly ordered 100 times. The average of area under the ROC curve (AUROC) 
was used as the criterium. In order to select the optimal number of component for 
PLS-DA, different numbers were tested (from 1 to the number of samples). 
Furthermore, the number of misclassifications and the Q² value were collected. A 
distribution was generated for the H0 hypothesis that no difference exists between the 
two classes. In the permutation test, the class labels of control and disease are 
permutated by randomly assigning them to different individuals. With ‘wrong’ class 
labels, a classification model is again calculated. The data were permutated 1000 
times. For each permutated set, the cross validation was repeated 20 times and the 
average parameter values were computed.  
  
2.4.2 Univariate analysis 
The bucket table created for the multivariate analysis was exported to Excel 
(Microsoft Office 2003) in order to carry out a Student’s t-test. P levels smaller than 
0.05 were considered to be significant. An advanced classifier, Support Vector 
Machine (SVM) [37], was applied to classify the samples based on the significantly 
differential buckets. Each sample contains one out of two possible labels, and is 
represented by a feature vector based on the values of the significant buckets. The 
data samples were randomly divided into 5 fractions, of which one was used for 
testing, whereas the others were used for training and validation. The data were 
randomly ordered 100 times. The average of area under the ROC curve (AUROC) 
was used as the criterium. To estimate the quality of the developed SVM model, the 
double cross-validation (2CV) strategy and permutation test described in [36] used for 
PLSDA were applied again. In all experiments, the SVM function in the package 
e1071 (version 1.5-22) in R (R version 2.7.2, http://www.r-project.org) was used with 
the default setting parameters, e.g. linear kernel and cost equals 1. 
 
3. Results  
3.1 Visual inspection of NMR spectra 
There is a lot of information comprised in 1H NMR spectra of serum and CSF 
samples. Visual inspection of the spectra can already reveal some interesting features 
in some cases. A representative 1H Carr-Purcell-Meiboom-Gill (CPMG) serum 
spectrum of both a wild type and a transgenic HD rat is represented in additional file 
A (see additional file A). The projection of all available serum spectra onto each other 
makes a clear differentiation between wild-type (WT) and HD rats possible. Peaks 
representing glucose and succinic acid seem to be elevated in spectra from HD rats 
  
(figure 1). This indicates that both glucose and succinic acid are increased in 
concentration in the serum of transgenic animals. Visual examination of an overlay of 
the CSF spectra does not indicate an immediate difference between WT and HD rats. 
 
3.2 PCA to detect outliers 
Principal component analysis (PCA) was applied on the data in order to uncover 
inherent similarities and differences potentially present within the spectral profiles. 
The scores plot of the first two principal components gives a representative overview 
of the data (figure 2). 
3.2.1 Serum samples 
The first principal component (PC1) accounts for 76.42 % of the total variation 
present in the dataset. The second principal component (PC2) accounts for an 
additional 10.02 % of the total variation. Data points lying outside the 95 % 
confidence ellipse (Hotelling T²) can be considered as outliers, i.e. observations that 
have an aberrant behaviour. As indicated in figure 2, two data point are laying outside 
the Hotelling T² plot. Reconsidering these spectra reveals that the water suppression 
technique, which has been used while acquiring the spectra, has caused a shift of the 
baseline in comparison with the other spectra. This slightly different prospect is 
revealed by this multivariate statistical tool. However, these two spectra are not 
discarded for further analysis, as their differences are not from a biological nature. 
3.2.2 CSF samples 
The scores plot of the first two principal components accounts for 45.57 % of the total 
variation present in the CSF dataset. Possible outliers present in the dataset were 
uncovered by spotting the data points lying outside the 95% confidence ellipse of this 
scores plot. Consecutive PCA indicate three data points (one WT and two HD 
samples) with an aberrant behaviour (see additional file B, additional file C and 
  
additional file D). Those spectra correspond with low available volume samples (< 40 
µL lyophilized). For this reason, these spectra were excluded from the dataset before 
further analysis. 
 
3.3 Discrimination between normal and pathological samples using PLS-DA 
A partial least squares - discriminant analysis (PLS-DA) model was developed in 
order to discriminate samples according to their class membership, i.e. healthy or HD. 
The results of this analysis are depicted in figure 3. The scores plot shows a 
reasonable separation between both sample groups. The corresponding loadings plot 
reveals the metabolites that are responsible for the observed separation. Annotation of 
the loadings was confirmed by a comparison with reference spectra of an in house 
database recorded at 700 MHz. A double cross-validation (2CV) strategy and 
permutation test were applied to estimate the quality of the developed PLS-DA model, 
as described in [36]. This yielded an area under the ROC curve (AUROC) of 84.90 % 
and 72.73 % for serum and CSF respectively. For all assessment parameters (Q² value 
and the number of misclassifications), there is a clear distinction between the 
permutation distribution and the original classification. This shows that the specific 
classification is significant (see Additional File E1 for serum and E2 for CSF). 
3.3.1 Serum samples 
The loadings coefficients responsible for the separation of the serum samples 
according to their pathological condition correspond to the metabolites glucose 
(δ3.28, δ3.38, δ3.43, δ3.48, δ3.53, δ3.73, δ3.78, δ3.83, δ3.88, δ3.93 and δ5.23), 
lactate (δ1.33 and δ4.13), lipids (δ0.83, δ0.88, δ1.23, δ1.28, δ1.58, δ2.03, δ2.23, 
δ2.73, δ2.78, δ5.28 and δ5.33), succinic acid (δ2.43), glutamine (δ2.13 and δ2.43) 
and NAA (δ2.03). An overview of these results is given in table 1. 
  
3.3.2 CSF samples 
The most relevant loadings in the separation of CSF samples according to their 
pathological condition are situated around δ3.38, δ3.43, δ3.48, δ3.73, δ3.78, δ3.83 
and δ3.88 (glucose) and δ1.33 (lactate). 
 
3.4 Discrimination between normal and pathological samples using a 
univariate analysis 
A Student’s t-test is used to uncover the metabolites that show a statistically 
significant concentration difference between the two observed populations. Thus, 
these metabolites can be used to differentiate HD from healthy samples. The bucket 
table, which was created for the multivariate analysis, was used as input variable for 
the univariate analysis. For each bucket, the corresponding p-value was calculated. A 
p-value smaller than 0.05 was considered as being significant.  
3.4.1 Serum samples 
The bucket comprising both the singlet peak of the methylene groups of succinic acid 
and the multiplet peak of CH2CO of glutamine was found to be significantly different 
between WT and TG rats. In order to assign this statistically significant difference 
unambiguously to the correct metabolite, both signals were integrated referenced to 
the methylene singlet of creatine at 3.93 ppm. A visual representation of these results 
is displayed in figure 4. These boxplots reveal that both metabolites contribute to the 
differentiation of the samples according to their genotype. Both glutamine (p < 0.05) 
and succinic acid (p < 0.005) were found to be significantly increased in HD rats 
compared to WT littermates. Glucose was found to be elevated in HD rats as well (p < 
0.05). Furthermore, NAA was decreased in HD rats (p < 0.05). Moreover, the bucket 
comprising the area between 4.30 and 4.25 ppm is found to be significantly decreased 
  
in HD rats. At present, we have not been able to identify the component(s) present in 
this bucket. These results are illustrated in figure 4. The thirteen most significant 
buckets for whom the p-value is smaller than 0.05, able in discriminating between 
healthy and HD samples, were used to build an SVM classifier. An area under the 
ROC curve (AUROC) of 71.44 % could be obtained. For all the assessment 
parameters, a clear distinction between the permutation distribution and the original 
classification is obtained. This demonstrates that the specific classification is 
significant (see Additional file E3). 
3.4.2 CSF samples 
In CSF, a student’s t-test could not reveal any statistically significant metabolite 
concentration difference between WT and HD rats. 
4. Discussion  
In this study we have shown that rats transgenic for the HD mutation can be 
discriminated from healthy, wild-type littermates even prior to the onset of motor 
deficits [38]. A comparable study was already executed by Tsang and co-workers on a 
different animal model [27]. However, there are some inconsistencies between the 
figures and text described in their paper. The metabolites they indicated in the 
loadingsplot of the serum samples correspond to those mentioned for urine samples in 
the text and vice versa.  
We used three different methods for the analysis. Visual inspection of the serum 
spectra already suggests that glucose as well as succinic acid levels are elevated in 
HD rats. These results are statistically confirmed by means of a univariate analysis. 
Moreover, the Student’s t-test discloses that glutamine and NAA are able to 
discriminate between HD and WT rats in serum samples. PLS, a supervised 
multivariate statistical technique, was performed in order to reveal the discriminative 
  
power of different metabolites between the studied groups. For the serum samples, the 
loadings which are able to separate healthy from pathological samples correspond to 
the metabolites glucose, glutamine, lipids, lactate, succinic acid and NAA. Regarding 
CSF spectra, visual inspection and univariate analysis are not able to discriminate WT 
from HD rats. PLS, on the other hand, distinguishes both glucose and lactate as 
discriminating metabolites. 
As well in CSF as in serum samples, glucose is indicated as a biomarker to detect 
Huntington Disease presymptomatically. Although the literature [2,4,39] exposes 
some evidence of diabetes in subjects with HD, plasma glucose measurements in the 
same transgenic rat model at different ages does not show elevated glucose levels 
[28]. Thus, the observed difference in glucose must have been caused by a 
perturbation in another metabolic pathway. Some evidence of a disturbed glucose 
metabolism in HD can be found in the literature [4,40,41]. A possible explanation for 
the observed increased concentrations of glutamine and glucose is also documented: 
according to Sibson et al. [32], there is a 1:1 stoichiometry between the consumption 
of glucose and the formation of glutamate. The observed increase in glutamine can 
reflect a decreased glutaminase activity. Glutaminase is a mitochondrial enzyme 
found in neurons that takes care of the conversion of glutamine in glutamate. A 
perturbation of the glutamate-glutamine cycling may indicate an impairment of 
energy metabolism and mitochondrial respiration [27]. Thus, a decrease in 
glutaminase activity precludes the conversion of glutamine into glutamate. Owing to 
this, the neurons will have a lack of glutamate for neurotransmission. Finally, this will 
result in an elevated concentration of glutamine and glucose (due to decreased glucose 
utilization) as observed in our experiments [4]. This theory can be affirmed by 
previous studies which also point to a disruption of energy metabolism in HD [42,43].  
  
In addition, the observed difference in lactate supports the theory of a deficiency of 
oxidative energy metabolism in rats transgenic for HD. The conversion of glucose to 
pyruvate during glycolysis involves the concomitant reduction of 2 moles of NAD+ to 
NADH. In cells undergoing an aerobic respiration, pyruvate is subsequently oxidized 
to acetyl-Coenzyme A (Acetyl-CoA), which in turn, enters the citric acid cycle. In this 
way, the NADH produced during glycolysis is reoxidized through the mitochondrial 
electron transport chain. However, a perturbation in the Krebs cycle or mitochondrial 
electron transport chain might prevent pyruvate to enter the oxidative energy 
metabolism. Since NADH needs to be reoxidized to NAD+ to maintain a steady state 
condition, an alternative pathway to transfer electrons is accomplished, i.e. the 
reduction of pyruvate to lactate by the catalyzed reaction of lactate dehydrogenase. As 
a result, an increased concentration of lactate, the end product of anaerobic glycolysis, 
indicates a defect in energy metabolism as well [44]. 
An elevated concentration of succinic acid is probably due to an inhibition of 
succinate dehydrogenase. This enzyme has two important functions in the 
mitochondria. First, it supports the oxidation of succinic acid to fumarate in the 
tricarboxylic acid (TCA) cycle. Second, it is linked to the respiratory chain, i.e. 
complex II of the mitochondrial electron transport chain [45,46]. A decrease in 
mitochondrial complex II activity has already been observed in HD [3,47,48]. Our 
finding of an elevated succinic acid concentration is therefore in line with these 
previous results. 
A decreased NAA concentration is known to be a marker of neuronal dysfunction 
[27,49]. Reduced NAA levels have been well documented for several neurological 
diseases, e.g. Alzheimer disease [50], Huntington Disease [4,27,51] and Parkinson 
Disease [17,50]. Moreover, in HD it clearly correlates with the duration of symptoms 
  
and the CAG repeat length [16,52]. The enzyme responsible for the synthesis of  
NAA, L-N-acetylaspartyl transferase, is exclusively found in mitochondria [50]. Since 
inhibitors of the mitochondrial respiratory chain seem to decrease the concentration of 
NAA [4], reduced NAA levels may reflect an impaired mitochondrial energy 
production [27].  
Obviously, a change in the concentration of each of these metabolites can be linked to 
a variety of conditions. However, the changes observed for all metabolites combined 
could allow for a more narrow correlation, i.e. with HD. 
5. Conclusions  
In conclusion, this study shows that metabolic alterations already emerge in the serum 
and CSF of these rats before overt symptoms of HD are manifested. In an early stage 
of the disease, metabolic alterations seem to be more pronounced in serum compared 
to CSF. All metabolites found being able at discriminating WT from HD rats point to 
a disruption of the mitochondrial respiratory chain and energy metabolism. These 
findings suggest that compounds which act on mitochondria might have a positive 
effect on HD pathology. Moreover, this study shows that 1H NMR spectroscopy is an 
appropriate tool to investigate the metabolic disturbance occurring in early stages of 
HD. A more profound knowledge of the disease pathology can be obtained by 
performing a metabolomic analysis of samples originating from more mature rats. 
Such an analysis could give more insight into the development of this disease, which 
in turn may lead to improved therapeutic interventions.  
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Figures 
Figure 1  - Visual comparison of serum spectra 
An overlay of all acquired 1H NMR 700 MHz serum spectra, a some representative 
peaks of glucose b signal of succinic acid. Spectra of wild-type rats are coloured 
black; those of HD rats blue 
  
Figure 2  - PCA to detect outliers 
PCA scores plot of the first and second principal component mapping the serum 
spectra of twelve wild-type and ten HD rats (females, 2 months old). The Hotelling T2 
ellipse is used to elucidate outliers. Colour coding: black = wild type rats, blue = HD. 
Figure 3  - PLS, clustering of samples according to their pathological condition 
a PLS scores plot of 1H NMR serum spectra of twelve wild-type (black squares) and 
ten HD (blue triangles) rats (females, 2 months old). b The corresponding loadings 
plot represents the variables attributable to the observed class separation. c PLS scores 
plot of 1H NMR CSF spectra of nine wild-type and eight HD rats (females, two 
months old). d The loading coefficient plot  corresponding to the scores plot (c). 
Figure 4  - Visualisation of the results obtained by univariate analysis 
A boxplot is used to visualize the data of the student’s t-test. The boxplot is based on 
the five-number-summary, i.e. the median (black line), 25 % quartile (lower box line), 
75 % quartile (upper box line), minimum (lower whisker) and maximum (upper 
whisker). This means that 50 % of the data points are situated in the box. The range 
between the 25 % quartile (Q25) and 75 % quartile (Q75) is called the interquartile 
range (IQR). Subsequently, the whiskers are calculated by the formula flower = Q25 – 
1.5*IQR for the lower whisker and respectively fupper = Q75 + 1.5*IQR for the upper 
whisker. a glucose, b glutamine, c NAA, d the unknown component in the bucket 
comprising the area between 4.30 and 4.25 ppm and e succinic acid. The boxplot of 
WT samples is coloured grey whereas the boxplot of TG samples has a blue colour. 
 
  
Tables 
Table 1  - Overview of the metabolites responsible for the separation of serum 
samples according to their pathological condition. 
 
Additional Files 
Additional file A  - Typical serum spectrum 
additional file A.pdf 
A representative 1H NMR 700 MHz CPMG serum spectrum of a wild-type (black) 
and HD (blue) rat. 
Additional file B – First PCA analysis of the CSF samples 
additional file B.pdf 
PCA scores plot of the first and second principal component mapping the CSF spectra 
of wild-type and HD rats. The Hotelling T2 ellipse is used to elucidate outliers. Colour 
coding: black = wild type rats, blue = HD. 
Additional file C – Second PCA analysis of the CSF samples 
additional file C.pdf 
A second PCA was performed after that the outlier visual in additional file B was 
removed from the dataset. The PCA scores plot of the first and second principal 
component mapping the CSF spectra of wild-type and HD rats resulting from this 
analysis is displayed. The Hotelling T2 ellipse is used to elucidate outliers. Colour 
coding: black = wild type rats, blue = HD. 
Additional file D – Third PCA analysis of the CSF samples 
additional file D.pdf 
A third PCA was performed after that the outliers visual in additional file B and 
additional file C were removed from the dataset. The PCA scores plot of the first and 
second principal component mapping the CSF spectra of wild-type and HD rats 
  
resulting from this analysis is displayed. The Hotelling T2 ellipse is used to elucidate 
outliers. Colour coding: black = wild type rats, blue = HD. 
Additional file E – Assessment of the classification results based on cross 
model validation and permutation tests. 
additional file E.pdf 
The parameters used to quantify the classifications are the number of 
misclassifications, Q2 and the area under the ROC curve. The three cases mentioned 
in the paper are in Additional file E1 (PLS-DA prediction results of serum spectra), 
Additional file E2 (PLS-DA prediction results of CSF spectra) and Additional file E3 
(SVM prediction results of serum spectra).  The solid circles are the actual values 
from the original classifications.  
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